Altimmune (ALT) Competitors $6.86 +0.15 (+2.24%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALT vs. APGE, TARS, AMPH, IOVA, IRON, BLTE, IBRX, WVE, ARQT, and INDVShould you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Apogee Therapeutics (APGE), Tarsus Pharmaceuticals (TARS), Amphastar Pharmaceuticals (AMPH), Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), Belite Bio (BLTE), ImmunityBio (IBRX), Wave Life Sciences (WVE), Arcutis Biotherapeutics (ARQT), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry. Altimmune vs. Apogee Therapeutics Tarsus Pharmaceuticals Amphastar Pharmaceuticals Iovance Biotherapeutics Disc Medicine Belite Bio ImmunityBio Wave Life Sciences Arcutis Biotherapeutics Indivior Apogee Therapeutics (NASDAQ:APGE) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, community ranking, analyst recommendations, valuation and institutional ownership. Do insiders & institutionals believe in APGE or ALT? 79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 36.1% of Apogee Therapeutics shares are owned by insiders. Comparatively, 4.1% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is APGE or ALT more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -199,076.92%. Apogee Therapeutics' return on equity of -21.81% beat Altimmune's return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -21.81% -20.94% Altimmune -199,076.92%-55.81%-50.60% Do analysts rate APGE or ALT? Apogee Therapeutics presently has a consensus price target of $89.71, suggesting a potential upside of 142.08%. Altimmune has a consensus price target of $19.71, suggesting a potential upside of 187.38%. Given Altimmune's higher possible upside, analysts clearly believe Altimmune is more favorable than Apogee Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Altimmune 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Which has higher valuation and earnings, APGE or ALT? Apogee Therapeutics has higher earnings, but lower revenue than Altimmune. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$83.99M-$2.42-15.31Altimmune$430K1,134.61-$88.45M-$1.55-4.43 Does the media prefer APGE or ALT? In the previous week, Apogee Therapeutics had 1 more articles in the media than Altimmune. MarketBeat recorded 1 mentions for Apogee Therapeutics and 0 mentions for Altimmune. Apogee Therapeutics' average media sentiment score of 0.15 beat Altimmune's score of 0.10 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Apogee Therapeutics Neutral Altimmune Neutral Does the MarketBeat Community believe in APGE or ALT? Altimmune received 33 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 73.08% of users gave Altimmune an outperform vote. CompanyUnderperformOutperformApogee TherapeuticsOutperform Votes24100.00% Underperform VotesNo VotesAltimmuneOutperform Votes5773.08% Underperform Votes2126.92% Which has more volatility and risk, APGE or ALT? Apogee Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. SummaryApogee Therapeutics beats Altimmune on 12 of the 18 factors compared between the two stocks. Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALT vs. The Competition Export to ExcelMetricAltimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$487.88M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-4.439.9189.4217.36Price / Sales1,134.61309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book2.496.055.314.79Net Income-$88.45M$154.90M$122.54M$225.00M7 Day Performance10.11%1.35%1.42%2.37%1 Month Performance-16.85%0.41%2.51%4.40%1 Year Performance-25.84%3.08%25.29%20.10% Altimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTAltimmune2.296 of 5 stars$6.86+2.2%$19.71+187.4%-25.8%$487.88M$430,000.00-4.4350APGEApogee Therapeutics2.3809 of 5 stars$40.37-1.7%$89.71+122.2%+10.0%$1.82BN/A-16.6891TARSTarsus Pharmaceuticals1.8274 of 5 stars$47.41-10.0%$54.20+14.3%+98.1%$1.81B$129.62M-12.4450AMPHAmphastar Pharmaceuticals4.4997 of 5 stars$37.67+3.6%$60.33+60.2%-35.1%$1.81B$723.55M12.561,620Short Interest ↑IOVAIovance Biotherapeutics4.1605 of 5 stars$5.92-7.5%$23.00+288.5%-24.0%$1.80B$90.86M-3.97500Gap UpIRONDisc Medicine2.6804 of 5 stars$58.32-1.6%$87.50+50.0%-10.0%$1.74BN/A-14.6530Short Interest ↑BLTEBelite Bio3.249 of 5 stars$55.90+0.8%$89.00+59.2%+21.7%$1.73BN/A-50.3610Gap UpIBRXImmunityBio2.4267 of 5 stars$2.47+2.1%$13.58+449.9%-18.3%$1.72B$7.33M-2.68590Short Interest ↑Gap UpWVEWave Life Sciences4.4278 of 5 stars$11.05-4.2%$22.22+101.1%+134.8%$1.69B$53.61M-9.95240ARQTArcutis Biotherapeutics2.3416 of 5 stars$13.74-0.5%$16.60+20.8%+290.2%$1.61B$138.71M-7.68150Gap UpINDVIndivior2.4343 of 5 stars$11.59-2.2%$16.00+38.1%-26.9%$1.60B$1.18B-289.681,164Short Interest ↑News CoveragePositive News Related Companies and Tools Related Companies Apogee Therapeutics Alternatives Tarsus Pharmaceuticals Alternatives Amphastar Pharmaceuticals Alternatives Iovance Biotherapeutics Alternatives Disc Medicine Alternatives Belite Bio Alternatives ImmunityBio Alternatives Wave Life Sciences Alternatives Arcutis Biotherapeutics Alternatives Indivior Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALT) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALT Stock Alerts